Enact vs Accelerant
ACT and ARX side by side, both in insurance agents, brokers, and service. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACT and ARX compare
Enact is the larger company, worth 1.4 times as much as Accelerant ($6.2B against $4.3B).
On earnings, Enact is cheaper: it trades at 9.5× trailing earnings, against 70.9× for Accelerant.
Accelerant grew revenue faster over the last twelve months (35.3% versus 2.5% for Enact).
Enact pays a dividend yielding 2.0%; Accelerant does not pay one.
Enact scores higher on the StockData Score (6 against 1 for Accelerant), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACT | ARX |
|---|---|---|
| Size and price | ||
| Market cap | $6.2B | $4.3B |
| Share price | $45.39 | $19.85 |
| Change, 1 year | 20.6% | 57.5% |
| Change, 5 years | 97.2% | 25.6% |
| Beta (5Y) | 0.51 | 0.36 |
| Employees | 419 | – |
| StockData Score | ||
| Total score | 6 (better) | 1 |
| Valuation score | 4 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 0 | 0 |
| Dividend score | 1 (better) | 0 |
| Valuation | ||
| P/E | 9.5× (better) | 70.9× |
| P/S | 5.0× | 3.7× (better) |
| P/B | 1.2× (better) | 5.9× |
| EV/EBITDA | – | 16.9× |
| PEG | 5.92 | – |
| Fair value | $102.00 | $12.64 |
| Margin of safety | 55.5% (better) | −57.1% |
| Growth | ||
| Revenue growth (TTM) | 2.5% | 35.3% (better) |
| Revenue growth, 5Y average | 2.2% | – |
| EPS growth (TTM) | 10.6% | – |
| EPS growth, 5Y average | 14.8% | – |
| Financial health | ||
| Altman Z-score | 3.38 (better) | 0.20 |
| Piotroski F-score | 5 | – |
| Dividends and buybacks | ||
| Dividend yield | 2.0% | – |
| Years of dividend growth | 1 | – |
| Buyback yield | 6.9% | – |
| Shareholder yield | 8.9% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 21.7% | 29.7% |
| Held by insiders | 90.6% | 73.7% |
| Insider net buying, 12 months | −$329M | −$21.6M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 23.2% | 5.2% |
Go deeper
- ACT stock overview
- ACT income statement
- ACT valuation and score
- ARX stock overview
- ARX income statement
- ARX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.